2 research outputs found
Π‘Π΅ΠΊΡΠ½Π΄Π°ΡΠ΅Π½ Π‘ΡΠ΅Π³ΡΠ΅Π½ ΡΠΈΠ½Π΄ΡΠΎΠΌ ΠΊΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π΅Π½ Π°ΡΡΡΠΈΡΠΈΡ
Secondary Sjogrenβs syndrome (sSS) is a connective tissue disease characterized by xeropthalmia and xerostomia, associated with another autoimmune disease. The prevalence of sSS in patients with rheumatoid arthritis (RA) is different in different countries, but is assumed at 10% of all RA patients and 20% of these have sub-clinical manifestations. This is a large subpopulation of patients with RA, especially taking into account that the clinical implications of their coexistence are not well explored. Aims: To analyze the effects of sSS on RA, the association between this syndrome and disease activity and disease evolution, presence of serological and immunological markers, disease duration and quality of life in patients with RA. Material and methods: We examined 42 patients, at the age of 18 to 70 years, diagnosed according to the criteria for classification and diagnosis by EULAR (2010). Twenty patients were diagnosed with RA and sSS, and 22 patients with RA without sSS. The groups were comparable regarding age, sex and disease duration. We analyzed the incidence of sSS, association with age, sex, demographic data, disease duration, extraarticular manifestations, and serologic tests (positive RF, anti-CCP) were also made. Disease activity was assessed by disease activity score (DAS28) and quality of life by the health assessment questionnaire-disability index (HAQ-DI). The number of tender and swollen joints was assessed, as well as pain level by using the visual analogue scale (VAS), sedimentation rate (ESR), CRP, and immunological tests(SSA, SSB, antidsDNA, ANA, antiU1snRNP) were also made. Results: In the analyzed patients there was no statistically significant difference in ESR, CRP, DAS28, HAQ-DI, seropositivity of RF and anti-CCP and the presence of antidsDNA, ANA or antiU1snRNP and disease duration. Patients in the RA group had more tender, swollen joints and VAS. There was a statistically significant difference in SSA and SSB levels. There was no significant difference in the treatment of patients from both groups.Conclusion: There was no statistically significant difference in the level of disease activity and quality of life in patients with RA compared to sSS group.Π‘Π΅ΠΊΡΠ½Π΄Π°ΡΠ½ΠΈΠΎΡ Π‘ΡΠ΅Π³ΡΠ΅Π½ΠΎΠ² ΡΠΈΠ½Π΄ΡΠΎΠΌ (ΡΠ‘Π‘) ΠΏΡΠ΅ΡΡΡΠ°Π²ΡΠ²Π° Π·Π°Π±ΠΎΠ»ΡΠ²Π°ΡΠ΅ Π½Π° ΡΠ²ΡΠ·Π½ΠΎΡΠΎ ΡΠΊΠΈΠ²ΠΎ ΠΊΠΎΠ΅ ΡΠ΅ ΠΊΠ°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΠ° Π³Π»Π°Π²Π½ΠΎ ΡΠΎ ΠΏΠΎΡΠ°Π²Π° Π½Π° ΠΊΡΠ΅ΡΠΎΡΡΠ°Π»ΠΌΠΈΡΠ° ΠΈ ΠΊΡΠ΅ΡΠΎΡΡΠΎΠΌΠΈΡΠ°, Π²ΠΎ ΡΠΊΠ»ΠΎΠΏ Π½Π° Π΄ΡΡΠ³ΠΈ Π°Π²ΡΠΎΠΈΠΌΡΠ½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°ΡΠ°. ΠΡΠ΅Π²Π°Π»Π΅Π½ΡΠΈΡΠ°ΡΠ° Π½Π° ΡΠ‘Π‘ ΠΊΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π΅Π½ Π°ΡΡΡΠΈΡΠΈΡ (Π Π) Π΅ ΡΠ°Π·Π»ΠΈΡΠ½Π° Π²ΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π΄ΡΠΆΠ°Π²ΠΈ, Π½ΠΎ ΡΠ΅ ΠΏΡΠ΅ΡΠΏΠΎΡΡΠ°Π²ΡΠ²Π° Π΄Π΅ΠΊΠ° ΠΈΠ·Π½Π΅ΡΡΠ²Π° ΠΎΠΊΠΎΠ»Ρ 10% ΠΎΠ΄ ΡΠΈΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ Π Π, ΠΏΡΠΈ ΡΡΠΎ ΠΎΠΊΠΎΠ»Ρ 20% ΠΎΠ΄ ΠΎΠ²ΠΈΠ΅ ΠΈΠΌΠ°Π°Ρ ΡΡΠΏΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΈ ΠΌΠ°Π½ΠΈΡΠ΅ΡΡΠ°ΡΠΈΠΈ. ΠΠ²Π° ΠΏΡΠ΅ΡΡΡΠ°Π²ΡΠ²Π° Π³ΠΎΠ»Π΅ΠΌΠ° ΡΡΠΏΠΏΠΎΠΏΡΠ»Π°ΡΠΈΡΠ° Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ Π Π, ΠΏΡΠΈ ΡΡΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΈΡΠ΅ ΠΈΠΌΠΏΠ»ΠΈΠΊΠ°ΡΠΈΠΈ Π½Π° ΠΊΠΎΠ΅Π³Π·ΠΈΡΡΠΈΡΠ°ΡΠ΅ΡΠΎ Π½Π° Π΄Π²Π΅ΡΠ΅ Π±ΠΎΠ»Π΅ΡΡΠΈ ΡΓ¨ΡΡΡΠ΅ ΡΠ΅ Π½Π΅Π΄ΠΎΠ²ΠΎΠ»Π½ΠΎ ΠΈΡΠΏΠΈΡΠ°Π½ΠΈ. Π¦Π΅Π»ΠΈ: ΠΠ° ΡΠ΅ Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠ°Π°Ρ Π΅ΡΠ΅ΠΊΡΠΈΡΠ΅ Π½Π° ΠΏΠΎΡΠ°Π²Π°ΡΠ° Π½Π° ΡΠ‘Π‘ Π²ΡΠ· Π±ΠΎΠ»Π΅ΡΡΠ°, ΠΎΠ΄Π½ΠΎΡΠ½ΠΎ ΠΏΠΎΠ²ΡΠ·Π°Π½ΠΎΡΡΠ° Π½Π° ΠΎΠ²ΠΎΡ ΡΠΈΠ½Π΄ΡΠΎΠΌ ΡΠΎ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠ° ΠΈ Π΅Π²ΠΎΠ»ΡΡΠΈΠ²Π½ΠΎΡΡΠ° Π½Π° Π±ΠΎΠ»Π΅ΡΡΠ°, ΠΏΡΠΈΡΡΡΡΠ²ΠΎΡΠΎ Π½Π° ΡΠ΅ΡΠΎΠ»ΠΎΡΠΊΠΈ ΠΈ ΠΈΠΌΡΠ½ΠΎΠ»ΠΎΡΠΊΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΈ, Π²ΡΠ΅ΠΌΠ΅ΡΡΠ°Π΅ΡΠ΅ΡΠΎ Π½Π° Π±ΠΎΠ»Π΅ΡΡΠ° ΠΈ ΠΊΠ²Π°Π»ΠΈΡΠ΅ΡΠΎΡ Π½Π° ΠΆΠΈΠ²ΠΎΡΠΎΡ ΠΊΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ Π Π. ΠΠ°ΡΠ΅ΡΠΈΡΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈ: ΠΠ΅Π° ΠΈΡΠΏΠΈΡΠ°Π½ΠΈ 42 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ Π½Π° Π²ΠΎΠ·ΡΠ°ΡΡ ΠΎΠ΄ 18 Π΄ΠΎ 70 Π³ΠΎΠ΄ΠΈΠ½ΠΈ, Π΄ΠΈΡΠ°Π³Π½ΠΎΡΡΠΈΡΠΈΡΠ°Π½ΠΈ ΡΠΏΠΎΡΠ΅Π΄ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌΠΈΡΠ΅ Π½Π° EULAR (2010).Β ΠΠ²Π°Π΅ΡΠ΅Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ Π±Π΅Π° ΡΠΎ Π Π ΠΈ ΡΠ‘Π‘ ΠΈ 22 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ Π Π Π±Π΅Π· ΠΏΡΠΈΠ΄ΡΡΠΆΠ΅Π½ ΡΠ‘Π‘. ΠΡΡΠΏΠΈΡΠ΅ Π±Π΅Π° ΡΠΎ ΡΠ»ΠΈΡΠ½ΠΈ ΠΊΠ°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ Π²ΠΎ ΠΎΠ΄Π½ΠΎΡ Π½Π° ΠΏΠΎΠ», Π²ΠΎΠ·ΡΠ°ΡΡ ΠΈ Π²ΡΠ΅ΠΌΠ΅ΡΡΠ°Π΅ΡΠ΅ Π½Π° Π±ΠΎΠ»Π΅ΡΡΠ°. ΠΠ΅Π° Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠ°Π½ΠΈ:Β ΠΏΠΎΡΠ°Π²Π°ΡΠ° Π½Π° ΡΠ‘Π‘ ΠΈ Π½Π΅ΡΠ·ΠΈΠ½Π°ΡΠ° Π·Π°Π²ΠΈΡΠ½ΠΎΡΡ ΠΎΠ΄ Π²ΠΎΠ·ΡΠ°ΡΡΠ° ΠΈ ΠΏΠΎΠ»ΠΎΡ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅, Π΄Π΅ΠΌΠΎΠ³ΡΠ°ΡΡΠΊΠΈΡΠ΅ ΠΏΠΎΠ΄Π°ΡΠΎΡΠΈ, ΡΡΠ°Π΅ΡΠ΅ΡΠΎ Π½Π° Π±ΠΎΠ»Π΅ΡΡΠ°, ΠΏΡΠΈΡΡΡΡΠ²ΠΎΡΠΎ Π½Π° Π²ΠΎΠ½Π·Π³Π»ΠΎΠ±Π½ΠΈ ΠΌΠ°Π½ΠΈΡΠ΅ΡΡΠ°ΡΠΈΠΈ, Π° Π±Π΅Π° Π½Π°ΠΏΡΠ°Π²Π΅Π½ΠΈ ΠΈ ΡΠ΅ΡΠΎΠ»ΠΎΡΠΊΠΈ ΡΠ΅ΡΡΠΎΠ²ΠΈ (ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΠΈΠΎΡ RF, anti-CCP). ΠΠΊΡΠΈΠ²Π½ΠΎΡΡΠ° Π½Π° Π±ΠΎΠ»Π΅ΡΡΠ° Π±Π΅ΡΠ΅ Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠ°Π½Π° ΠΏΡΠ΅ΠΊΡ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΡ Π½Π° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡ Π½Π° Π±ΠΎΠ»Π΅ΡΡ - DAS28 (Disease Activity Score 28), Π° ΠΊΠ²Π°Π»ΠΈΡΠ΅ΡΠΎΡ Π½Π° ΠΆΠΈΠ²ΠΎΡ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΠΏΡΠ΅ΠΊΡ HAQ-DI (Health Assessment Questionnaire β Disability Index). ΠΠ΅ΡΠ΅ Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠ°Π½ Π±ΡΠΎΡΠΎΡ Π½Π° Π±ΠΎΠ»Π½ΠΈ ΠΈ ΠΎΡΠ΅ΡΠ΅Π½ΠΈ Π·Π³Π»ΠΎΠ±ΠΎΠ²ΠΈ, VAS (Π²ΠΈΠ·ΡΠ΅Π»Π½Π° Π°Π½Π°Π»ΠΎΠ³Π½Π° ΡΠΊΠ°Π»Π° Π½Π° Π±ΠΎΠ»ΠΊΠ°), ΡΠ΅Π΄ΠΈΠΌΠ΅Π½ΡΠ°ΡΠΈΡΠ° Π½Π° Π΅ΡΠΈΡΡΠΎΡΠΈΡΠΈ (ESR), CRP, Π° Π±Π΅Π° Π½Π°ΠΏΡΠ°Π²Π΅Π½ΠΈ ΠΈ ΠΈΠΌΡΠ½ΠΎΠ»ΠΎΡΠΊΠΈ ΡΠ΅ΡΡΠΎΠ²ΠΈ (SSA, SSB, antidsDNA, ANA, antiU1snRNP) ΠΈ ΠΏΠΎ ΠΏΠΎΡΡΠ΅Π±Π° Π΄ΡΡΠ³ΠΈ ΠΈΠΌΡΠ½ΠΎΠ»ΠΎΡΠΊΠΈ ΠΈ ΡΠ΅ΡΠΎΠ»ΠΎΡΠΊΠΈ ΡΠ΅ΡΡΠΎΠ²ΠΈ). Π Π΅Π·ΡΠ»ΡΠ°ΡΠΈ: ΠΠ°Ρ ΠΈΡΠΏΠΈΡΠ°Π½ΠΈΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ Π½Π΅ΠΌΠ°ΡΠ΅ ΡΡΠ°ΡΠΈΡΡΠΈΡΠΊΠΈ ΡΠΈΠ³Π½ΠΈΡΠΈΠΊΠ°Π½ΡΠ½Π° ΡΠ°Π·Π»ΠΈΠΊΠ° Π²ΠΎ ESR, CRP, DAS28, HAQ-DI, ΡΠ΅ΡΠΎΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΠΎΡΡ ΠΊΠΎΠ½ RF ΠΈΠ»ΠΈ anti-CCP, ΠΊΠ°ΠΊΠΎ ΠΈ ΠΏΡΠΈΡΡΡΡΠ²ΠΎΡΠΎ Π½Π° antidsDNA, ANA ΠΈΠ»ΠΈ antiU1snRNP, ΠΊΠ°ΠΊΠΎ ΠΈ ΡΡΠ°Π΅ΡΠ΅ Π½Π° Π±ΠΎΠ»Π΅ΡΡΠ°. ΠΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ Π²ΠΎ Π Π Π³ΡΡΠΏΠ°ΡΠ° Π±Π΅Π° Π²ΠΎ ΠΏΠΎΠ³ΠΎΠ»Π΅ΠΌ Π±ΡΠΎΡ, ΡΠΎ ΠΏΠΎΠ²Π΅ΡΠ΅ ΠΎΡΠ΅ΡΠ΅Π½ΠΈ Π·Π³Π»ΠΎΠ±ΠΎΠ²ΠΈ ΠΈ ΠΏΠΎΠ²ΠΈΡΠΎΠΊΠ° VAS. ΠΠΎΡΡΠΎΠ΅ΡΠ΅ ΡΡΠ°ΡΠΈΡΡΠΈΡΠΊΠΈ ΡΠΈΠ³Π½ΠΈΡΠΈΠΊΠ°Π½ΡΠ½Π° ΡΠ°Π·Π»ΠΈΠΊΠ° Π²ΠΎ ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΠΎΡΡΠ° Π½Π° SSA ΠΈ SSB Π°Π½ΡΠΈΡΠ΅Π»Π°ΡΠ° Π²ΠΎ Π΄Π²Π΅ΡΠ΅ Π³ΡΡΠΏΠΈ. ΠΠ΅ΠΌΠ°ΡΠ΅ ΡΠ°Π·Π»ΠΈΠΊΠ° Π²ΠΎ Π»Π΅ΠΊΡΠ²Π°ΡΠ΅ΡΠΎ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ Π²ΠΎ Π΄Π²Π΅ΡΠ΅ Π³ΡΡΠΏΠΈ. ΠΠ°ΠΊΠ»ΡΡΠΎΠΊ: ΠΠ΅ ΠΏΠΎΡΡΠΎΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠΊΠΈ ΡΠΈΠ³Π½ΠΈΡΠΈΠΊΠ°Π½ΡΠ½Π° ΡΠ°Π·Π»ΠΈΠΊΠ° Π²ΠΎ Π½ΠΈΠ²ΠΎΡΠΎ Π½Π° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡ Π½Π° Π±ΠΎΠ»Π΅ΡΡΠ° ΠΈ ΠΊΠ²Π°Π»ΠΈΡΠ΅ΡΠΎΡ Π½Π° ΠΆΠΈΠ²ΠΎΡ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΡΠΎ Π Π Π²ΠΎ ΡΠΏΠΎΡΠ΅Π΄Π±Π° ΡΠΎ ΠΎΠ½ΠΈΠ΅ ΡΠΎ ΡΠ‘Π‘
Immunoglobulin Classes and Subclasses in Macedonian Elderly People Maced
Abstract Aim: The aim of this study was to determine the association of HLA-A, -C and -B genes with ankylosing spondylitis in patients from the Republic of Macedonia. Material and Methods: This study included 307 subjects (250 healthy individuals and 57 patients with ankylosing spondylitis who were diagnosed at the University Clinic of Rheumatology in Skopje). The HLA typing of class 1 (HLA-A, HLA-C and HLA-B) genes was performed using the method of Reverse Line Strip, after isolation of DNK from the blood leucocytes with the standard phenol-chloroforme method. The HLA sub typing of HLA-B*27 was performed with high resolution single-strand polymorphism